Drug Trial Radar · NCT00940498
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jan 2010
Primary completion
Aug 2011
Study completion Oct 2012
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.
Conditions
- Neoplasms
Interventions
PF-05212384 (also known as PKI-587)Drug
Intravenous dosing once weekly infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
- Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
- Number of Participants With Laboratory AbnormalitiesTime frame: Baseline up to Cycle 14 (each cycle is 28 days)
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Baseline up to Day 28
- Recommended Phase-2 Dose (RP2D)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Insitute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Memorial Sloan-Kettering Cancer Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute, Tennessee Oncology, PLLC
Nashville, Tennessee
Hospital General Vall D'Hebron
Barcelona, Spain
King's College London
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.